Welcome to VHEST Study Official Website

VHEST stands for "Valsartan in Hypertension, Efficacy, Safetey & Tolerability" VHEST is an Observational Study on the Efficacy, Safety and Tolerability of Valsartan and Valsartan HCT Combination in Managing Patients with Essential Hypertension in Actual Practice in Syria. Clinical trials of different types have shown clearly that high blood pressure is associated with increased cardiovascular morbidity and mortality, and lowering high blood pressure reduces these complications, mainly, heart failure, myocardial infarction & stroke. Suppression of the Renin-Angiotensin Aldestrone System (RAAS) by means of Angiotensin Converting Enzyme (ACE) inhibitors has been employed successfully for long time in the treatment of essential hypertension. However, ACE inhibitors are associated with characteristic adverse events such as Angioneurotic edema and dry cough. Prior to participation in the study, Ibn-Alhaytham Pharmaceutical Industry cardiovascular line -medical representatives will visit the selected physicians for signing up a participation agreement stating physician's approval to conduct the study according to the plans provided by Ibn-Alhaytham Pharmaceutical Industry �Scientific Department and to provide the company with the case report form for each patient after study completion. For more information about the study check the VHEST Protocol